Sung Ji Nam
Stock Analyst at Scotiabank
(3.77)
# 699
Out of 5,072 analysts
83
Total ratings
50.72%
Success rate
8.99%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $108.42 | -44.66% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $64.51 | +16.26% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $226.78 | +21.26% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $590.83 | -0.14% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $131.45 | -4.91% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $39.90 | +0.25% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $8.17 | +389.60% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $7.63 | -21.36% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.85 | +116.22% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $2.32 | -13.79% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $101.29 | -27.93% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $19.66 | -38.96% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $403.42 | +11.55% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $32.01 | +93.69% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $47.37 | -7.11% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.75 | +97.18% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.71 | +27.39% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $29.56 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $108.42
Upside: -44.66%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $64.51
Upside: +16.26%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $226.78
Upside: +21.26%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $590.83
Upside: -0.14%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $131.45
Upside: -4.91%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $39.90
Upside: +0.25%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $8.17
Upside: +389.60%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $7.63
Upside: -21.36%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.85
Upside: +116.22%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $2.32
Upside: -13.79%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $101.29
Upside: -27.93%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $19.66
Upside: -38.96%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $403.42
Upside: +11.55%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $32.01
Upside: +93.69%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $47.37
Upside: -7.11%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.75
Upside: +97.18%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.71
Upside: +27.39%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $29.56
Upside: -